SAN DIEGO, Feb. 25 /PRNewswire-FirstCall/ -- Bio-Matrix Scientific Group, Inc. (OTC Bulletin Board: BMSN) announced today that it has added two members to newly created positions on its management team. Feng Lin, M.D., Ph.D. has joined the biotech research and development company as Laboratory/Scientific Director and Marilyn Panahi is serving as Quality Assurance Director.
"Dr. Feng Lin and Marilyn Panahi bring tremendous expertise to the administrative operations of BMSN's laboratories to ensure all of the varied facets meet government regulations and compliance," said David Koos, Chairman and CEO, BMSN.
As Laboratory/Scientific Director, Dr. Lin is responsible for the overall operation, leadership, direction, and administration of BMSN's Laboratory in accordance with Federal and State Regulations governing laboratories.
As Quality Assurance Director, Ms. Panahi is responsible for managing and assuring regulatory compliance requirements including validation, customer complaints, and review of product manufacture records, audits, and quality assurance documentation. .
Dr. Feng Lin has a strong background in drug/DNA in vivo delivery,
oncology and tumor immunotherapy, DNA vaccination, cell and molecular biology,
and animal model work. He also has extensive experience with tissue imaging,
DNA vaccine design, antibody- and cell-based assay. Previously, Dr. Lin was a
Senior Research Scientist, Research & Development with Inovio Biomedical
Corp., San Diego. He received his M.D. from Central
Marilyn Panahi brings more than 15 years experience in the implementation and management of the EPA's Good Laboratory Practice Standards (GLPS) Compliance Monitoring Program and the FDA's Good Manufacturing Practices (GMP)/Quality Systems Regulation.
Previously, Ms. Panahi was Quality Manager, Therapheresis, Inc., San
Diego. Ms. Panahi is a graduate of
About Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN)
Bio-Matrix Scientific Group, Inc., based in San Diego, is a biotech research and development company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market. The company aligns itself with strategic partners that offer key technologies in biomedical device development, tissue partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation. Bio-Matrix's new 15,000 sq. ft. facility, located in the heart of San Diego's biotechnology corridor, houses the company's two secure Cryogenic Stem Cell Banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing laboratory, hematology, microbiology and flow cytometry laboratories.
|SOURCE Bio-Matrix Scientific Group, Inc.|
Copyright©2009 PR Newswire.
All rights reserved